Browsing by Author "Yorgancioglu, AA"
Now showing 1 - 14 of 14
Results Per Page
Sort Options
Item Evaluation of physians, patients, relatives and society of opinions on the told lung cancer diagnosisDatli, U; Çelik, P; Havlucu, Y; Göktalay, T; Coskun, AS; Yorgancioglu, AAIntroduction: In our country, this is usually done by patient relatives. In this study, we aimed to investigate the thought of doctors who done the diagnosis, doctors who arrange the treatment, first degree relatives of patients with lung cancer, and population as a control. Materials and Methods: 310 subjects (100 doctors, 110 first degree realtives of patients, and 100 subjects as a control) were included to the study. The mean age was 39.77 +/- 11.44 years and there was 170 females. 46% of doctors were giving cancer treatment (chemotheraphy/radiotheraphy). Results: 84.5% of subjects were answered the question (Do you want to know the diagnosis of lung cancer if you are lung cancer?) as yes and the answers were not different between groups (p> 0.05). 72 of doctors were giving information about diagnosis of patients. This ratio was 89.1% in doctors who arrange lung cancer treatment whereas it was 57.4% in doctors who do not arrange cancer treatment. The percent age of learning of diagnosis of lung cancer throughout the time in doctors, population, and patient's relatives were 19%, 34%, and 59% respectively (p< 0.05). Information about quality of life was more important in relatives of patients (87%) than population (65%) and doctors (63%) (p< 0.05). Quality of life was more important for doctors who arrange lung cancer treatment (76.7)% than doctors who did not (48.8%) (p< 0.05). Patients who were more children wanted to stay with their family at end stage of disease (p< 0.05). Conclusion: According to this study we think that doctors should say the diagnosis of lung cancer in the form of they understand, inform the patients and relatives about treatment, and quality of life and this can increase patient trust to doctor and compliance of patients to the treatment.Item Smoking prevalence of elementary school students in ManisaAlkaç, C; Çelik, P; Özyurt, BC; Sakar Coskun, A; Alpaydin, AÖ; Göktalay, T; Demet, M; Yorgancioglu, AAIntroduction: In this study it is aimed to evaluate the prevalence of smoking, factors affecting smoking status, and the attitudes of the elementary school students towards the smoking prohibition law which was approved in July 2009, in city. Materials and Methods: The universe of this descriptive study was 6th -7th -8th class, 8236 urban and 4937 semi-urban, total 13.173 elementary schools students in city center. Study population was determined on the basis of a previous study in which the smoking trial prevalence was found 17.5%, 831 students in 6 urban 3 semi-urban, total 9 schools were chosen randomly. A questionnaire was prepared investigating smoking status, the effects of smoking and family history. Among the 9 chosen schools, the questionnaire was applied to 615 students. SPSS 14.0 statistical package was used. Results: Forty-seven percentages of the students were female. Prevalence of smoking trial was found 23.5% (16% in urban, 35% in semi-urban schools) while the prevalence of smoking was 7.1% (1.7% in urban, 15.7% in semi-urban schools). Mean age of first smoking trial was 10.04 +/- 2.3. The smoking prohibition law was supported by 86.6% of the students, the warnings on the cigarette package was thought to be effective by 43.3% students and 35.2% of the students were exposed to passive smoke. Male gender, social status, education level of the family, smoker family member or close friends were found to be important risk factors for smoking prevalence of the students. Conclusion: The early onset of smoking should guide the smoking struggle be concentrated in elementary school especially in semi-urban areas where the smoking prevalence is high.Item 2019 ARIA Care Pathways for Allergic Rhinitis-TurkeyYorgancioglu, AA; Gemicioglu, B; Cingi, C; Kalayci, Ö; Kalyoncu, AF; Bachert, C; Hellings, P; Pfaar, O; Schünemann, HJ; Wallace, D; Bedbrook, A; Czarlewski, W; Bousquet, JThe evaluation of real-life integrated care pathways (ICPs) was recommended for digitally enabled, integrated, person-centered care for rhinitis and asthma multimorbidity embedding environmental exposure. ICPs are structured multidisciplinary care plans detailing key steps of patient care. They promote the translation of guideline recommendations into local protocols and their application to clinical practice. In allergic rhinitis, there is an urgent need to develop next-generation guidelines for pharmacotherapy and ICPs for allergen immunotherapy. A meeting was held in Paris on December 3, 2018, during which two separate documents were produced. An executive summary is presented in this article, which will be customized in different countries or regions in order to adjust the conclusions of the papers for local use and health systems.Item ARIA 2016 executive summary: integrated care pathways for predictive medicine across the life cycleYorgancioglu, AA; Kalayci, Ö; Cingi, C; Gemicioglu, B; Kalyoncu, AF; Agache, I; Bachert, C; Bedbrook, A; Canonica, GW; Casale, T; Cruz, A; Fokkens, WEJ; Hellings, P; Samolinski, B; Bousquet, JThe Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization (WHO) workshop in 1999. The initial goals were (i) to propose a new allergic rhinitis classification, (ii) to promote the concept of multi-morbidity in asthma and rhinitis and (iii) to develop guidelines with all stakeholders for global use in all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK (MACVIA (Contre les MAladies Chroniques pour un VIeillissement Actif)-ARIA Sentinel NetworK) uses mobile technology to develop care pathways in order to enable the management of rhinitis and asthma by a multi-disciplinary group or by patients themselves. An App (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.Item Evaluation of asthma and COPD awareness in primary care doctors in TurkeyErsu, R; Karakoç, GB; Yildiz, F; Köktürk, N; Mungan, D; Ekinci, B; Gemicioglu, B; Yorgancioglu, AAIntroduction: Chronic pulmonary diseases cause significant morbidity and mortality. However awareness about the risk factors, symptoms, diagnosis and traetment of these disorders is low among patients and health care providers. Our aim was to evaluate the awareness of asthma and chronic obstructive pulmonary disease among primary care doctors. This study was performed by the national Global Alliance Against Chronic Respiratory Diseases programme. Material and Methods: Primary care doctors employed by the Ministry of Healthy were included to the study. Turkish Statistical Institute randomly selected 680 doctors. Questionnaires evaluating the awareness of asthma and COPD which were developed by the Turkish Thoracic Society COPD and asthma assemblies were completed online by these doctors. Results: 84% of the doctors described asthma as airway obstruction. Dyspnea was reported as the most common symptom of asthma (78.8%) and inspiratory rhonci was reported as the most common physical exam finding (42.3%). Around 50% of doctors thought impairment of pulmonary function tests (PFT) was important for diagnosis and evaluation of severity of asthma while 24.2% thought physical exam was more important. When treatment options were evaluated 87.6% chose inhaled treatment for asthma. COPD was described as bronchiectasis and chronic bronchitis by 9.1%, chronic bronchitis and emphysema by 61.6%, chronic bronchitis and asthma by 22.2% and asthma and emphysema by 7.1%. 1.2% of the doctors did not consider cigarette smoking as a risk factor for COPD. PFT was recommended for diagnosis by 83%. Most correctly differentiated asthma and COPD. Bronchodilators were the first choice for COPD by 72.5%. Conclusion: Awareness is low for asthma and COPD among primary care doctors. Awareness should be raised among health care professionals for these diseases with high economical burden to improve outcome.Item MASK (Mobile Airways Sentinel networK) in Turkey-the ARIA integrated mobile solution for allergic rhinitis and asthma multimorbidityYorgancioglu, AA; Gemicioglu, B; Kalayci, O; Kalyoncu, AF; Cingi, C; Murray, R; Onorato, G; Arnavielhe, S; Bedbrook, A; Bousquet, JmHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. Allergic Rhinitis and its impact on asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity MASK-rhinitis (Mobile Airways Sentinel networK), the Phase 3 ARIA initiative, is based on the freely available app. The Allergy Diary is used by people who were informed by physicians, searched the internet, Apple App Store, Google Play. Turkish Validation has been available and currently in use.Item Pregnancy Outcomes of the Asthma Patients on Omalizumab in TurkeyGemicioglu, B; Yalçin, AD; Karakaya, G; Ozdemir, L; Keren, M; Yorgancioglu, AA; Ediger, D; Bavbek, S; Havlucu, Y; Oguzulgen, I; Özseker, ZFItem Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthmaYorgancioglu, AA; Pavord, I; Brusselle, G; Pitrez, P; Oosterholt, S; Pg, A; Della Pasqua, OItem COVID-19 Pandemic and the Global Perspective of Turkish Thoracic SocietyKöktürk, N; Itil, BO; Altinisik, G; Adigüzel, N; Akgün, M; Akyildiz, L; Altin, S; Arikan, H; Ates, G; Ay, P; Aykaç, N; Babayigit, C; Bostan, P; Cinel, G; Çalisir, HC; Çelik, P; Çetinkaya, PD; Dagli, E; Demir, AU; Demir, C; Dikensoy, Ö; Edis, EÇ; Elbek, O; Erdinç, M; Ergan, B; Eyüboglu, AFÖ; Gemicioglu, B; Göksel, T; Gülhan, E; Gültekin, Ö; Gürkan, CG; Gürgün, A; Havlucu, Y; Basoglu, OK; Karakurt, S; Karkurt, Z; Kilinç, O; Kocabas, A; Kul, S; Müsellim, B; Nayci, S; Özkan, M; Pinarer, Ö; Saltürk, C; Sandal, A; Sayiner, A; Sen, E; Simsek, GÖ; Karadag, BT; Akyil, FT; Töreyin, ZN; Uçan, ES; Küçük, FÇU; Varol, A; Yasin, Y; Yildiz, T; Yorgancioglu, AA; Bayram, HIt has been more than 3 months now since the first case of COVID-19 was reported in Turkey. Globally, the number of confirmed cases and deaths reached 9,653,048 and 491,128 respectively, as reported by 216 countries by June 27, 2020. Turkey had 1,396 new cases, 194,511 total cases, and 5,065 deaths by the same date. From the first case until today, the Turkish Thoracic Society (TTS) has been very proactive in educating doctors, increasing public awareness, undertaking academic studies, and assisting with public health policies. In the present report, social, academic, and management perspectives of the pandemic are presented under appropriate subtitles. During this critical public health crisis, TTS has once again demonstrated its readiness and constructive stance by supporting public health, healthcare workers, and the environment. This review summarizes the perspective of TTS on each aspect of the COVID-19 pandemic and casts light on its contributions.Item Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key ChangesReddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LPThe Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes. (C) 2021 by the American Thoracic Society. Reprinted with permission.Item Global Initiative for Asthma Strategy 2021 Executive Summary and Rationale for Key ChangesReddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LPThe Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.Item Global Initiative for Asthma Strategy 2021 Executive Summary and Rationale for Key ChangesReddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LPThe Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.Item Global initiative for Asthma Strategy 2021: executive summary and rationale for key changesReddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LPThe Global initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g. medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not he treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.Item Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key ChangesReddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LPThe Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes. (C) 2022 . by the American Thoracic Society, which grants unconditional and unlimited licenses to the European Respiratory Journal, Respirology, Archivos de Bronconeumologia, and Journal of Allergy and Clinical Immunology: In Practice.